Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

Background: The <i>TOP2A</i> and <i>ERBB2</i> genes are co-amplified in about 40% of HER2 positive (HER2+) breast cancers. Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by <i>TOP2A</i>), has demonstrated clinical activity in metastatic breast ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Clelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, Stelly Ballet, Anne Vincent-Salomon, Perrine Vuagnat, Audrey Bellesoeur, Jean-Yves Pierga, Marc-Henri Stern, Francois-Clement Bidard, Florence Lerebours
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-04-01
Colecção:Cancers
Assuntos:
HER2 metastatic breast cancer
oral etoposide
trastuzumab
<i>TOP2A/ERBB2</i> co-amplification
Acesso em linha:https://www.mdpi.com/2072-6694/14/9/2114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados